NasdaqGM:NAMSBiotechs
Analyst Highlights MACE-4 Endpoint in PREVAIL Study Could Be a Game Changer for NAMS
Earlier this week, a Jefferies analyst reiterated a positive outlook on NewAmsterdam Pharma, highlighting the company's pursuit of a broader FDA label through the PREVAIL study using the MACE-4 endpoint for obicetrapib.
The analyst emphasized that obicetrapib's unique position in the cardiovascular market could influence NewAmsterdam's future competitive advantages.
We'll explore how the clinical validity of the MACE-4 endpoint shapes the investment narrative for NewAmsterdam Pharma's growth...